Bio-Techne Corp
TECH
ISIN US09073M1045 / Valor 25995847
Bio-Techne Corp
UMushroom community rating:
About company
Bio-Techne Corp is a global company that specializes in providing a wide range of products in the fields of hematology, chemistry, immunology, and measurement of blood gases. Through strategic acquisitions, the company has expanded its offerings to include monoclonal and polyclonal antibodies, antigens, and other biological reagents, as well as innovative ubiquitin-related research products. With a product line extending to over 24,000 items, Bio-Techne Corp focuses on serving the diagnostics industry by offering a comprehensive catalog of high-quality products, with 95% of them manufactured in-house.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (20.08.2024):
Fourth Quarter Revenue
Bio-Techne Corp reported a 2% increase in net sales for the fourth quarter of fiscal 2024, reaching $306.1 million. Organic revenue saw a 1% rise, with acquisitions contributing an additional 1%. Foreign currency exchange and a business held-for-sale did not materially impact these results.
GAAP Earnings
For the fourth quarter of fiscal 2024, Bio-Techne Corp's GAAP earnings per share (EPS) was $0.25, a decrease from $0.47 in the same quarter last year. GAAP operating income dropped 52% to $45.8 million, compared to $94.5 million in the fourth quarter of fiscal 2023, with a GAAP operating margin of 15.0%.
Non-GAAP Earnings
Bio-Techne Corp's adjusted EPS for the fourth quarter of fiscal 2024 was $0.49, down from $0.55 in the same period last year. Adjusted operating income decreased by 9% to $101.8 million, with an adjusted operating margin of 33.5%, compared to 37.1% in the fourth quarter of fiscal 2023.
Full Year Revenue
For the full fiscal year 2024, Bio-Techne Corp reported a 2% increase in net sales, totaling $1.2 billion. Organic revenue grew by 1%, with acquisitions contributing another 1%. The company experienced a favorable impact from foreign currency exchange.
Full Year GAAP Earnings
Bio-Techne Corp's GAAP EPS for the full fiscal year 2024 was $1.05, down from $1.76 in the previous year. GAAP operating income decreased by 31% to $206.7 million, with a GAAP operating margin of 17.8%, compared to 26.3% in fiscal 2023.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
11943 M
Market cap (USD)
297,456
Daily traded volume (Shares)
76.81 / 74.68
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
